Pharmacogenomics defines how genes can affect a person’s response to drugs. It is relatively a new field and combines pharmacology and genomics. The aim of Pharmacogenomics Market is to develop effective and safe medications. Moreover by pharmacogenomics, drugs doses can be tailored to a person’s genetic makeup. The field of pharmacogenomics is predicted to treat a wide range of health problems including cardiovascular diseases, Alzheimer disease, cancer, HIV/AIDS, and asthma, in near future. The Global Pharmacogenomics Market is expected to grow at a ~CAGR of 5.8% during the forecast period.
Get a Sample Report @ https://www.marketresearchfuture.com/sample_request/1177 .
As indicated by the Organization for Economic Co-operation and Development (2017), biotech R&D in the business endeavor area was 11.3%, and 9.4% for U.S. also, France separately in 2014. Also, in 2016, as per the organization BIOCOM AG, the aggregate turnover for the Germany based biotech organizations was USD 3.7 billion. The above information reasons that the biotechnology business is growing. This developing biotech part alongside the rising medicinal services uses, and expanding enthusiasm for altered medications will drive the market development. In any case, absence of mindfulness and absence of consistency in pharmacogenomics items will control the market development amid the figure time frame.
The key players for the global pharmacogenomics market are Myriad Genetics, Inc. (U.S.), 23andMe, Inc. (U.S.), Pathway Genomics (U.S.), GeneTech (U.S.), GeneDx. (U.S.), Future Science Group (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Assurex Health, Inc. (U.S.), and others.
The Americas dominate the global pharmacogenomics market owing to a well-developed healthcare sector and presence of developed economies like the U.S. and Canada. Moreover, increasing number of patients suffering from cardiovascular diseases and rising healthcare expenditure have boosted the growth of the market in America. In 2016, according to the Centres for Diseases Control and Prevention in the U.S., heart disease was the leading cause of death for both men and women. Moreover, it was also estimated that the healthcare expenditure for heart diseases in the U.S. reaches USD 200 billion each year.
Europe is the second largest Pharmacogenomics Industry, followed by Asia Pacific. Availability of funds for research and development along with government support and presence of huge patient population within the region will drive the market growth during the forecast period. Moreover, the presence of the developed economies like Germany and France within the region fuels the market growth.
Asia Pacific is the fastest growing region for the market due to the presence of a huge patient population, continuously developing economies like India and China and presence of huge opportunities in the market drives the market. According to the Indian Brand Equity Foundation in 2016, the Indian biotech industry is estimated to reach USD 100 billion by 2025 from USD 7 billion in 2015 with a CAGR of 30.46%.
On the other hand, the Middle East & Africa has the least share in the global pharmacogenomics market due to presence of poor economy, low per capita healthcare expenditure and stringent government policies especially in the Africa region. The majority of the market of this region is held by the Middle East due to a well-developed healthcare sector and huge healthcare expenditure. Moreover, developed economies like Dubai, Saudi Arabia, Dubai, besides others fuels the market growth within the Middle East & Africa region.
Ask to Expert @ https://www.marketresearchfuture.com/enquiry/1177 .
- Report Prologue
- Market Introduction
- Research Methodology
- Market Dynamics
- Market Factor Analysis
- Global Pharmacogenomics Market, By Application
- Global Pharmacogenomics Market, By Therapeutic Application
- Global Pharmacogenomics Market, By Methods
- Global Pharmacogenomics Market, By Region
- Company Profile
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Research Future
+1 646 845 9312